New drug combo trial offers hope for advanced prostate cancer patients
NCT ID NCT06568094
Summary
This study is testing whether a new oral drug called HRS-5041, when given alongside other standard prostate cancer treatments, is safe and effective for men with advanced disease. It will involve about 100 male participants to find the best dose and see how well it controls cancer progression. The main goals are to check for side effects and measure how the treatment affects prostate-specific antigen (PSA) levels, a key marker of prostate cancer activity.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PROSTATE CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Shanghai Jiao Tong University School of Medicine, Renji Hospital
RECRUITINGShanghai, Shanghai Municipality, 200433, China
Contact
-
The Second Affiliated Hospital of Harbin Medical University
RECRUITINGHarbin, Heilongjiang, 150000, China
Contact
Conditions
Explore the condition pages connected to this study.